Our magazine is free!

for living with diabetes

GSK’s new T1 drug fails phase III clinical trial

GlaxoSmithKline says that Otelixizumab, a Type 1 drug currently under development, has failed in a phase III clinical trial. The drug has been in development in partnership with Tolerx, according to a recent article from Reuters.

The drug was designed for people with newly diagnosed diabetes. However, the drug failed to preserve beta cell function. Analysts had modest expectations for the drug after a similar offering from Eli Lilly failed in October. The company said it would continue to explore different dosing regiments. However, a second similar clinical study has been halted.

As reported by Diabetes Newshound

Sign up to our Magazine »

Leave a Comment

Submit Comment »

No Comments Yet!


nl-imageDirect to your inbox, our

free online magazine.

Sign up for the Desang Diabetes Magazine for new products, special offers and news.

*We will never email you more often than once a week (usually once a month). You can easily unsubscribe at any time. It’s finger-pricking good!

Close Don't show again